Sepsis-Associated Hypotension

Cross-source consensus on Sepsis-Associated Hypotension from 1 sources and 5 claims.

1 sources · 5 claims

How it works

Sepsis causes about 50 million cases annually worldwide and is a major contributor to preventable deaths and hospital costs. — Midodrine for Sepsis Treatment and Early Vasopressor Weaning (MID-STEP): protocol for a pragmatic randomised clinical trial
More than 60% of patients with sepsis develop hypotension, hyperlactatemia, or require vasopressor therapy. — Midodrine for Sepsis Treatment and Early Vasopressor Weaning (MID-STEP): protocol for a pragmatic randomised clinical trial
Sepsis-associated hypotension is primarily driven by pathological vasodilation. — Midodrine for Sepsis Treatment and Early Vasopressor Weaning (MID-STEP): protocol for a pragmatic randomised clinical trial
Current guidelines endorse early vasopressor initiation even when central venous access is not available. — Midodrine for Sepsis Treatment and Early Vasopressor Weaning (MID-STEP): protocol for a pragmatic randomised clinical trial
Aggressive fluid bolusing to delay vasopressors can cause cardiac, respiratory, and renal complications from volume overload. — Midodrine for Sepsis Treatment and Early Vasopressor Weaning (MID-STEP): protocol for a pragmatic randomised clinical trial